Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (±)-epibatidine in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 3, 1998, Pages 847-853

  Curzon, Peter ^a   Nikkel, Arthur L ^a   Bannon, Anthony W ^a   Arneric, Stephen P ^a   Decker, Michael W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; ANALGESIC AGENT; AZETIDINE DERIVATIVE; CHLORISONDAMINE; EPIBATIDINE; FUSED HETEROCYCLIC RINGS; LIDOCAINE; LOCAL ANESTHETIC AGENT; MECAMYLAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; CYTISINE; FORMALDEHYDE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM; PAIN ASSESSMENT; RAPHE NUCLEUS; RAT; SPRAGUE DAWLEY RAT; ANIMAL EXPERIMENT; ANTINOCICEPTION; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAPHE MAGNUS NUCLEUS;

ANALGESICS, NON-NARCOTIC; ANESTHETICS, LOCAL; ANIMALS; AZETIDINES; BICYCLO COMPOUNDS, HETEROCYCLIC; CHLORISONDAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; LIDOCAINE; MALE; MECAMYLAMINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PAIN MEASUREMENT; PYRIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032254323     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Abreo MA, Lin NH, Garvoy DS, Gunn DE, Hettinger AM, Wasicak JT, Pavlik PA, Martin YC, Donnelly-Roberts D, Andersen DJ, Campbell JE, Piattoni-Kaplan M, Sullivan, JP, Williams M, Arneric SP and Holladay MW (1996) Novel 3-pyridil ethers with subnanomolar affinity for central nicotinic acetylcholine receptors. J Med Chem 39:817-825.
2. Briggs ÇA, McKenna DG and Piattoni-Kaplan M (1995) Human a 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583-590.
3. Brioni JD, Morgan SJ, O'Neill AB, Sykora TM, Postl SP, Pan JB, Sullivan JP and Arneric SP (1996) In vivo" profile of novel nicotinic ligands with CNS selectivity. Med Chem Res 6:487-510.
4. Clarke PBS and Kumar R (1983a) Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80:587-594.
5. Clarke PBS and Kumar R (1983b) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329-337.
6. Curzon P, Nikkel AL, and Decker MW (1998) Central antinociceptive mechanisms of A-85380, a nicotinic acetylcholine receptor (nAChR) agonist. Soc Neurosci Abstr 24:85.
7. Damaj MI, Creasy KR, Grove AD, Rosencrans JA and Martin BR (1994) Pharmacological effects of epibatidine optical isomers. Brain Res 664:34-40.
8. Damaj MI, Glassco W, Dukat M, May EL, Glennon RA and Martin BR (1996) Pharmacology of novel nicotinic analogs. Drug Deu Res 38:177-187.
9. Decker MW and Majchrzak MJ (1993) Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats. Behav Neural Biol 60:163-171.
10. Dubuisson D and Dennis SG (1977) The formalin test: A quantitative study of the analgesic effect of morphine, meperidine and brain stem stimulation in rats and cats. Pain 4:161-174.
11. El-Bizri H and Clarke PBS (1994) Regulation of nicotinic receptors in rat brain after quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine. Br J Pharmacol 113:917-925.
12. Flores CM, Rogers SW, Pabreza LA, Wolfe BB and Kellar KJ (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of a4 and 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
13. Gopalakrishnan M, Buisson B, Tourna E, Giordano T, Campbell JE, Hu I, Bertrand C, Donnelly-Roberts D, Arneric SP and Sullivan JP (1995) Pharmacological characterization of the human al neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur J Pharmacol 290:237-246.
14. Hargreaves K, Dubner R, Brown F, Flores C and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
15. Iwamoto ET (1989) Antinociception after nicotine administration into the mesopontine tegmentum of rats: Evidence for muscarinic actions. J Pharmacol Exp Ther 251:412-421.
16. Iwamoto ET (1990) Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther 257:120-133.
17. Kumar R, Reavill C and Stolerman IP (1987) Nicotine cue in rats: Effects of central administration of ganglionic blocking drugs. Br J Pharmacol 90:239-246.
18. Litchfield JT and Wilcoxon F (1948) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113.
19. Martin TJ, Suchocki J, May EL and Martin BR (1990) Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. J Pharmacol Exp Ther 254:45-51.
20. Menzaghi F, Whelan KT, Risbrough VB, Rao T and Lloyd GK (1996) Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther 280:384-392.
21. Pertovaara A, Weä H and Hämäläinen MM (1996) Lidocaine in the rostroventralmedial medulla and the periaqueductal gray attenuates allodynia in neuropathic rats. Neurosci Lett 218:127-130.
22. Qian C, Li T, Shen TY, Libertine-Garahan L, Eckman J, Biftu T and Ip S (1993) Epibatidine is a nicotinic analgesic. Eur J Pharmacol 250:R13-R14.
23. Rogers DT and Iwamoto ET (1993) Multiple spinal mediators in parenteral nicotineinduced antinociception. J Pharmacol Exp Ther 267:341-349.
24. Sullivan JP, Briggs CA, Donnelly-Roberts D, Brioni JD, Radek RJ, McKenna DG, Campbell JE, Arneric SP, Decker MW and Bannon AW (1994a) (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med Chem Res 4:502-516.
25. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, Kang C-H, Adama P, Piattoni-Kaplan M, Buckley MJ, Gopalakrishnan M, Williams M and Arneric SP ( 1994b) ( ±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 271:624-631.
26. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger A-M, Garvey DS, Wasicak JT, Holladay MW, Williams M and Arneric SP (1996) A-85380 [3-(2S)-azetidinylmethoxy)pyridine]: In vitro pharmacological properties of a novel, high affinity a4/32 nicotinic acetylcholine receptor ligand. Neuropharmaeology 35:725-734.